Lee, Seonghyun Yoon, Hyunho Hong, Seol Hee Bang, Eun-Kyung Kwon, Sung Pil Kwak, Hye Won Park, Hyo-Jung Lee, Jisun Park, Hyeong-Jun Bae, Seo-Hyeon Youn, Hyewon Keum, Gyochang Lee, Shee Eun Nam, Jae-Hwan 2024-01-22T01:19:26Z 2024-01-22T01:19:26Z 2024-01-19 2023-05 0022-1767 https://pubs.kist.re.kr/handle/201004/147680 The viral E6 and E7 oncoproteins of human papillomavirus (HPV) are strongly associated with cervical cancer. We developed and assessed the efficacy of an mRNA-HPV therapeutic vaccine (mHTV), containing the E6 and E7 proteins, in C57BL/J mice. mHTV generated robust T cell-mediated immune responses and induced short-lived effector and E7 tetramer-specific T cells. mHTV immunization significantly suppressed tumor growth in mice implanted with TC-1 tumor cells and improved overall survival. The re-transplantation of tumor cells into mice that survived the primary tumor challenge after primary vaccination led to the complete inhibition of tumor progression in all mHTV-treated mice. This showed that mHTV can effectively suppress cancer recurrence. mHTV also increased the number of tumor-infiltrating lymphocytes in the tumor tissues. When mice were implanted with TC-1 tumor cells after mHTV vaccination, most of the immunized mice were protected from the tumor challenge. In conclusion, mHTV showed considerable potential as not only a therapeutic vaccine, by efficiently killing cancer cells, but also as a prophylactic vaccine by enhancing T cell-mediated immune responses. English AMER ASSOC IMMUNOLOGISTS mRNA-HPV Therapeutic Vaccine Encoding E6 and E7 Improves Therapeutic Potential in HPV-mediated Cancer Conference 1 IMMUNOLOGY2023™ IMMUNOLOGY2023™ US Washington, DC, USA 2023-05-11 JOURNAL OF IMMUNOLOGY 001106506503233